We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Clinical Trials Demonstrate Potential of New Psoriasis Drug

By LabMedica International staff writers
Posted on 22 Jun 2015
Print article
Image: Psoriasis plaques in the skin (Photo courtesy of Wikimedia Commons).
Image: Psoriasis plaques in the skin (Photo courtesy of Wikimedia Commons).
Two clinical trials involving the candidate psoriasis drug ixekizumab showed that it was more effective than the currently used drug etanercept or a placebo.

Ixekizumab is a humanized monoclonal antibody that selectively neutralizes interleukin 17A. This cytokine is now recognized as one of the primary factors behind the development of the characteristic red, scaly plaques of psoriasis. High levels of this cytokine have also been associated with several chronic inflammatory diseases including rheumatoid arthritis and multiple sclerosis.

Investigators at the University of Manchester (United Kingdom) took part in two prospective, double-blind, multicenter, phase three studies (UNCOVER-2 and UNCOVER-3) that evaluated the efficacy of ixekizumab for treatment of psoriasis in comparison to etanercept or a placebo.

Etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF (tumor necrosis factor) receptor to the constant end of the IgG1 antibody. It is a large molecule, with a molecular weight of 150,000 Daltons, which binds to TNFalpha and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, and rheumatoid arthritis. However, serious infections and sepsis, including fatalities, have been reported with the use of etanercept including reactivation of latent tuberculosis and hepatitis B infections.

Results published in the June 10, 2015, online edition of the journal the Lancet related to more than 2,500 psoriasis patients. Half were treated with ixekizumab once every two or four weeks, while the other half were given etanercept or a placebo.

Both ixekizumab dose regimens had greater efficacy than a placebo or etanercept over 12 weeks in the two independent studies. Around half of the patients treated with ixekizumab showed improvement as early as week four of the trial and up to 71% demonstrated a high level of improvement by week 12.

“The objective for treating psoriasis has been to reduce the visible symptoms,” said first author Dr. Christopher E M Griffiths, professor of dermatology at the University of Manchester. “But new drugs are fast showing us that a realistic goal for all patients should be attaining clear skin and this trial very much sets us on that path. What we saw in this trial was not just the physical aspects of the disease clearing up, but people on the new drug also reporting a marked improvement in their quality of life as they felt more confident and suffered less from itching – far more than in the other two groups.”

Related Links:

University of Manchester


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Unit-Dose Packaging solution
HLX
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
New
Urine Collection Container
Urine Monovette

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.